<DOC>
	<DOCNO>NCT01209754</DOCNO>
	<brief_summary>The Prevention Agent Pregnancy Exposure Registry , also know EMBRACE ( Evaluation Maternal Baby Outcome Registry After Chemoprophylactic Exposure ) prospective observational cohort investigation exposure study agent investigation HIV prevention . The study population consist female participant identify become pregnant participation microbicide PrEP trial , plan exposure pregnancy safety study well baby result pregnancy . This study enroll baby yet reach 1 year birth date .</brief_summary>
	<brief_title>EMBRACE ( Evaluation Maternal Baby Outcome Registry After Chemoprophylactic Exposure )</brief_title>
	<detailed_description>The Prevention Agent Pregnancy Exposure Registry , also know EMBRACE ( Evaluation Maternal Baby Outcome Registry After Chemoprophylactic Exposure ) prospective observational cohort study maternal exposure investigational HIV prevention agent . Approximately 550 pregnant participant 400 live infant offer enrollment . The study population consist current recent female participant identify become pregnant microbicide PrEP trial , plan exposure pregnancy safety study . This study also include infant result pregnancy . This protocol monitor adverse pregnancy delivery outcomes , monitor prevalence major malformation , evaluate growth parameter infant first year life , evaluate prevalence persistence HIV drug resistance mutation cohort infant either expose active study agent expose active study agent utero .</detailed_description>
	<criteria>Mother cohort 1 . Able willing provide write informed consent take part study 2 . During participation parent protocol , has/had know confirmed pregnancy , meet least one follow set criteria A B : A . Two consecutive monthly study visit , least 14 day apart , positive pregnancy test , absence signs/symptoms miscarriage participant report pregnancy termination . B . One follow assessment : Auscultation fetal heart tone Positive pregnancy test confirm clinic staff presence clinically confirm enlarged uterus Positive pregnancy test confirm clinic staff presence miss menses ( menses occur least 60 day first day last menses ) participant report ( For amenorrheic irregularly cycling woman , two consecutive positive hCG test ( criterion A ) clinical sign pregnancy include criterion B listing use confirm MTN016 eligibility ) . Clinical assessment fetal movement Demonstration pregnancy ultrasound 3 . Able willing provide adequate locator information , define site SOPs Note : Participants currently enrol engage followup parent protocol participate EMBRACE . Infant cohort 1 . Has write inform consent provide parent ( ) /guardian take part study manner consistent local standard , site Institutional Review Board ( IRB ) guidance US Code Federal Regulations ( CFR ) 2 . Born EMBRACE participant mother pregnancy concurrent participation parent study Mother cohort 1 . Has condition opinion investigator designee , would complicate interpretation study outcome data , make participation study unsafe , otherwise interfere achieve study objective 2 . Pregnancy outcome occur great one year ago Infant cohort 1 . Has condition , opinion investigator designee , would complicate interpretation study outcome data , make participation study unsafe , otherwise interfere achieve study objective 2 . Has reach 1 year birth date</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Chemoprophylactic Exposure</keyword>
	<keyword>Mother</keyword>
	<keyword>Infant</keyword>
	<keyword>malformation</keyword>
	<keyword>HIV</keyword>
</DOC>